Our top pick for
Moleculin Biotech, Inc is a biotechnology business based in the US. Moleculin Biotech shares (MBRX) are listed on the NASDAQ and all prices are listed in US Dollars. Moleculin Biotech employs 11 staff and has a market cap (total outstanding shares value) of USD$50.6 million.
|Latest market close||USD$0.73|
|52-week range||USD$0.323 - USD$1.55|
|50-day moving average||USD$0.7665|
|200-day moving average||USD$0.9358|
|Wall St. target price||USD$3.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.32|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-18)||-5.19%|
|1 month (2020-10-23)||-4.45%|
|3 months (2020-08-25)||-17.98%|
|6 months (2020-05-22)||N/A|
|1 year (2019-11-25)||-29.81%|
|2 years (2018-11-23)||-46.72%|
|3 years (2017-11-24)||-58.29%|
|5 years (2015-11-22)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-45.75%|
|Return on equity TTM||-110.72%|
|Market capitalisation||USD$50.6 million|
TTM: trailing 12 months
There are currently 2.6 million Moleculin Biotech shares held short by investors – that's known as Moleculin Biotech's "short interest". This figure is 11.3% down from 2.9 million last month.
There are a few different ways that this level of interest in shorting Moleculin Biotech shares can be evaluated.
Moleculin Biotech's "short interest ratio" (SIR) is the quantity of Moleculin Biotech shares currently shorted divided by the average quantity of Moleculin Biotech shares traded daily (recently around 404352.72161742). Moleculin Biotech's SIR currently stands at 6.43. In other words for every 100,000 Moleculin Biotech shares traded daily on the market, roughly 6430 shares are currently held short.
However Moleculin Biotech's short interest can also be evaluated against the total number of Moleculin Biotech shares, or, against the total number of tradable Moleculin Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moleculin Biotech's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Moleculin Biotech shares in existence, roughly 40 shares are currently held short) or 0.0475% of the tradable shares (for every 100,000 tradable Moleculin Biotech shares, roughly 48 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Moleculin Biotech.
Find out more about how you can short Moleculin Biotech stock.
We're not expecting Moleculin Biotech to pay a dividend over the next 12 months.
Over the last 12 months, Moleculin Biotech's shares have ranged in value from as little as $0.323 up to $1.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moleculin Biotech's is 2.1975. This would suggest that Moleculin Biotech's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. The company has partnerships and collaboration agreement with The University of Texas MD Anderson Cancer Center, Emory University, Mayo Clinic Research Endeavor, The University of Iowa, Medical University of Gdansk, University of Bergen, DERMIN Sp. z o. o., and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.